“New Standard of Care”? Lung Cancer KOLs on KRASCENDO-1 and ESMO26
ESMO26 lung KOL reactions: KRASCENDO-1 OS HR 0.56, PERSEE PFS HR 0.56, DeLLphi-305 OS HR 0.42, and four China-only ADC trials in NSCLC.
The Curator Era: 6 Ways AI Is Already Rewiring the Oncology Community
83% of surveyed oncology clinicians use AI on their own and 71% have no policy. Six trends, the tools doctors use and build, in oncologists' own words.
ESMO 2026: Oncology is the Tip of the Spear for AI in Healthcare
ESMO 2026: oncology leads OpenEvidence use (JAMA), and digital opinion leaders moved INTerpath-001, NADINA and KRASCENDO-1 debates at X speed.
KOL Reactions: Practice Changing…Or NOT — 10 ESMO26 Controversies Oncologists Debated on X
10 #ESMO26 trials oncologists called practice changing—or not. Verbatim KOL posts from X on both sides of PERSEE, DeLLphi-305, INTerpath-001 and more.
ESMO 2026 Day 3: Top Trials and KOL Reactions
ESMO 2026 Day 3: KRASCENDO-1 and the crossover question, SAFFRON, HARMONi-GI1, CLARITY-Gastric01, PERSEE, LITESPARK-012, NADINA and more, with physician reactio…
ESMO 2026: Top Melanoma Trials and KOL Voices
ESMO 2026 Madrid melanoma, October 23–26: investigational INTerpath-001 led physician discussion, followed by the NADINA 3-year update, STARBOARD and TIL data, …
ESMO 2026: Top GI Cancer Trials and KOL Voices
ESMO 2026 Madrid GI cancers, October 23–26: HARMONi-GI1, CLARITY-Gastric01, HERIZON-GEA-01, SANO, G-HOPE-001, IROCAS and AZUR-1, with verbatim physician reactio…
ESMO 2026: Top Gynecologic Cancer Trials and KOL Voices
ESMO 2026 Madrid gynecologic cancers, October 23–26: TroFuse-005 and KEYNOTE-C93 from Presidential Symposium III, plus NRG-GY020, DUO-E and BEHOLD-1, with verba…
ESMO 2026: Top Breast Cancer Trials and KOL Voices
ESMO 2026 Madrid breast cancer, October 23–26: NATALEE, KEYNOTE-B49, PANKU-Breast01, FOURLIGHT-1, SWITCH, BRIDGET, OptiTROP-Breast01 and DESTINY-Breast09, with …
ESMO 2026: Top Lung Cancer Trials and KOL Voices
ESMO 2026 Madrid lung cancer, October 23–26: DeLLphi-305, KRASCENDO-1, SAFFRON, PERSEE, OptiTROP-Lung06, PANKU-Lung01 and HERON-Lung01, with verbatim physician …
ESMO 2026: Top GU Cancer Trials and KOL Voices
ESMO 2026 Madrid GU cancers, October 23–26: VOLGA, KEYNOTE-866, DASL-HiCaP, LITESPARK-012 and TALAPRO-3, FDA approved October 26, with verbatim physician reacti…
ESMO 2026 Days 1–2: Top Trials and KOL Reactions
ESMO 2026 Days 1-2: a standing ovation for DeLLphi-305 and the crossover question physicians raised, plus INTerpath-001, VOLGA, NATALEE, PANKU-Breast01 and more…
The ESMO 2026 Debates from the KOL Social Media Threads
ESMO 2026 physician debates on X, verbatim: INTerpath-001 vs neoadjuvant IO, NATALEE's nominal OS p-value, me-too HER2 ADCs, pCR vs EFS in bladder cancer, KEYNO…
AI-Native Workflows with Your Favorite Tools: 5 Prompts to Copy
Paste a KOL Pulse trial or conference page into NotebookLM, Perplexity, Claude or ChatGPT. Five copy-ready prompts: trial timelines, trial-vs-trial tables, sent…
ENERGIZE and KEYNOTE-866: Two Negative Phase 3 MIBC Trials at ESMO 2026, and the NIAGARA Question
ESMO 2026: perioperative nivolumab (ENERGIZE, EFS HR 0.94) and pembrolizumab (KEYNOTE-866, EFS HR 0.88, OS HR 1.00) with gem/cis did not improve EFS in cisplati…
The INTerpath-001 Leak: An Embargo Break, a 25% Drop, and What Oncologists Said
ESMO lifted the LBA1 embargo after INTerpath-001 results leaked early: RFS HR 0.58 (95% CI 0.45–0.75). Moderna fell 25%. What oncologists and investors said.
PATINA Trial - Dr. Olivier Told You So!!!
Feb: Timothée Olivier, MD, flagged PATINA's open-label, investigator-assessed PFS. Jun: FDA approval. Oct: EMA says benefits “had not been demonstrated.”
The KOL Layer Now Loads Before the Publication Layer in Oncology
AI assistants can now find what oncologists said about a trial before the full paper is published. Why the open KOL layer, not the sponsor's publication plan, i…
“More Market Than Medical” — The Oncologists Doubting Galleri as the FDA Panel Meets
FDA's first MCED advisory panel meets Sept 23 as NEJM publishes NHS-Galleri's missed primary endpoint (stage III/IV IRR 1.03). Verbatim skepticism from Drs. Bur…
Etcamah (Camizestrant) Is FDA Approved — and Some KOLs Still Agree With ODAC's No Vote
SERENA-6 KOL sentiment after the Etcamah (camizestrant) FDA approval: Tatiana Prowell, Angela DeMichele's ASCO plenary takeaways, Gyawali and other voices who s…
The DOL Launch: How Digital Opinion Leaders Ran Rasonque's Day One Product Launch
How KOLs and DOLs ran their own product launch for Rasonque (daraxonrasib) in pancreatic cancer: sequencing, patient selection, biomarkers, and patient educatio…
Key Learnings from COSMO 2026 for Digital Opinion Leaders and Patient Advocates
What the COSMO 2026 faculty slides teach oncology's digital voices and patient advocates: misinformation rates by platform, who patients trust, AI chatbot quali…
Gedatolisib (Revtorpyk) Is FDA Approved: What Breast Oncology KOLs Said on Day One
What breast oncology KOLs said within hours of the gedatolisib (Revtorpyk) FDA approval: doublet vs triplet, weekly-IV burden, and the 2.0-month control arm.
Can OpenEvidence Keep Up With This Weekend's Lung Cancer KOLs?
The DAVA thoracic summit is invite-only — but its insights are public. A 5-minute exercise to build your own OpenEvidence-style tool with NotebookLM.
How I Built a Claude Science Skill That Writes Its Own FDA-Approval Comparison Tables
New from Anthropic: Claude Science, an AI research workbench. What it is, how to get it, and the first thing I built with it — a skill that generates auditable …
Who Fills the Lung-Cancer Trial Skeptic Role? The Independent Voices to Watch
Jack West joined Summit Therapeutics and Vinay Prasad served at the FDA - so who fills the lung-cancer skeptic role? The independent academic voices to watch, w…
Who's Moving the Needle in Lung-Cancer Trial Conversations on X?
The real lung-cancer KOL network on X, by engagement and peer amplification across 15 trials: whose voice shapes sentiment on MARIPOSA, CROWN, FLAURA2, LIBRETTO…
5 Reasons Every Oncology MSL Should Rely on KOL Pulse
Why should oncology MSLs add KOL Pulse AI: an open, AI-native intelligence layer on top of closed KOL databases like Veeva Link and Larvol — real-time congress …
MajesTEC-3 Network Analysis
Majestec-3 Network analysis
Dr. Vinay Prasad's Views on Key ASCO Breast Cancer Trials
Dr. Vinay Prasad is now Director of FDA's CBER Division, Review his thoughts on NATALEE, DESTINY-Breast04, and postMONARCH breast cancer clinical trials
DESTINY-Breast09 is Trending, What About PATINA?
Breast Cancer experts from the global KOL community have been buzzing about DESTINY-Breast09 and PATINA clinical trials. Track their social media insights.
MARIPOSA Trial Investigator Shares the Inside Scoop
Blog review of a powerful video discussion by Dr. Marcelo Corassa reviewing the important clinical trials of EGFRmut NSCLC including MARIPOSA and FLAURA2
How Does KOL Pulse AI Compare to the 800lb Gorillas? (Veeva Link, IQVIA, etc)
Discover how KOL Pulse AI challenges legacy SAAS platforms by delivering precise, real-time insights tailored for the oncology research & MSL community
The UK Just Approved Blenrep for Myeloma, What do Top KOLs think?
Key Opinion Leaders in Multiple Myeloma express their beliefs regarding the potential return of Blenrep to the US based on DREAMM-7 and DREAMM-8
Lung Cancer KOLs Use Memes to Communicate EGFRmut Treatments
Lung Cancer Key Opinion Leaders, KOLs, are using memes to communicate the complicated treatment decisions for EGFRmut NSCLC based on the FLAURA2, MARIPOSA
DeLLphi-304 Tweet Leaders
Amgen just released a Press release on the DELLPHI-304 data, Check out what top KOLs have to say about this data set.
CheckMate 8HW YouTube Review: Oncology Brothers with Dr. Alok Khorana
KOL Pulse review of the Oncology Brothers podcast featuring Dr. Alok Khorana. covering the CheckMate 8HW pivotal trial fcr MSI high colorectal cancer
CheckMate 8HW KOL Network Visualization
AI generated network visualization of the KOL influencers of the CheckMate 8HW clinical trial discussion.
CheckMate 8HW KOL Leaderboard
KOL Pule AI Pie Chart Leaderboard of CheckMate 8HW KOL influencers by engagement
CheckMate 8HW Sentiment BCG Matrix
KOL PulseAI demo of the Sentiment BCG Matrix for the CheckMate 8HW clinical trial.
CheckMate 8HW AI Sentiment Dashboard Demo
Producing an AI generated professional social media sentiment analysis of the CheckMate 8DW Clinical trial
DESTINY-Breast06 AI Chatbot for MSLs
AI chatbot for DESTINY-Breast06 trial that summarizes social media insights from oncology KOLs—expert reactions, trends, and key commentary in real time
MARIPOSA Trial: AI Generated Global Network Visualization
AI Generated Network Visualization of Global Lung Cancer Leaders discussing MARIPOSA clinical trial on X. Leaders include Dr. Stephen Liu, Dr.Erik Singhi
Dr Girard Provides an Excellent Review of MARIPOSA Survival Data from #ELCC25 on YouTube
The KOL Pulse AI tool allows a user to create a table with the leaderboard of KOL influencers and identify their key interactions and topics from #ELCC25
AI Generated Leaderboard: #ELCC25 Conference
The KOL Pulse AI tool allows a user to create a table with the leaderboard of KOL influencers and identify their key interactions and topics from #ELCC25
NIAGARA Trial : FDA Approval Launch Pack for Clinicians
Key Opinion Leaders in GU Oncology have provided a plethora of resources to help clinicians process the recent FDA approval of durvalumab for MIBC based on the …
Is Ivonescimab Too Good To Be True? Highlights of Dr. John Heymach's Uromigos Podcast
Dr. John Heymach provided the Uromigos with a review on the HARMONi-2 trial of ivonescimab in NSCLC
ASCO23 Flashback: Dr. Prasad's Video Criticisms of ADAURA
Amid the hype of the plenary session at ASCO23, Dr. Vinay Prasad criticized the study design and ethical implementation of AstraZeneca's ADAURA trial.
The KOL Pulse AI Advantage for Oncology Professionals
KOL Pulse AI has many advantages for MSL organizations vs the internal IT data lake structure. Hand-curated data sets = High TRUST and AUTHORITY
GU Cancer Researchers Discuss Latest Breakthroughs at #GU25
Leaders in GU Cancers discussed the latest breakthroughs and clinical trial updates. KOLs include Dr. Plimack, Dr. Choueiri, Dr. Powles, and Dr. Beckerman
Lung Cancer Researchers Gather at #ttlc25
Lung Cancer Leaders gathered in Huntington Beach, CA to discuss Targeted Therapies in Lung Cancer at the #TTLC25 meeting.KOL Pulse AI measured the influence.
AI Generated KOL Network Mapping - ivonescimab discussion
Key Opinion Leader Network Mapping through KOL Pulse AI generated social network visualization of KOL discussions of HARMONi-A from #ASCO24
Using AI to Understand ivonescimab - KOL Pulse AI Demo
Akeso biopharma published a preprint of the mechanism of action of ivonescimab. Can the KOL Pulse AI provide context to KOL questions about HARMONi-A?
Measuring KOL Sentiment of Oncology Clinical Trials
Sentiment analysis of Key Opinion Leader Tweets at Medical conferences like ASCO24 and SABCS24 has tremendous value to Pharma, physicians, and payers.
MARIPOSA Social Conversations Amid Promising New OS Data for Patients with EGFR-mutated NSCLC
MARIPOSA Social Network Diagram
Not All AI is Created Equal
Not All AI is Created Equal: Why Data Quality and Data Prompting Matter
SABCS24 Social Influence In Action
SABCS24 Social Influence Network
ASH24 Social Influencer Conversations in Full Swing
ASH24 Social Influence Network
HARMONi-2 Trial: Ivonescimab vs. Pembrolizumab
On September 8th, HARMONI-2 trial data will be presented at World Lung by Akeso. In 2022, Summit, founded by Bob Duggan, bet $500M Cash and $5B Total that ivone…
The Wild West of World Lung Cancer #WCLC24
On September 8th, HARMONI-2 trial data will be presented at World Lung by Akeso. In 2022, Summit, founded by Bob Duggan, bet $500M Cash and $5B Total that ivone…
Top Lung Cancer Digital Opinion Leaders of #ASCO24
Top 10 Digital Opinion Leaders in Lung Cancer in the US including Dr. Stephen Liu, Dr. Nathan Pennell, Dr. Patrick Forde, Dr. Jack West, Dr. Brendon Stiles
LUNAR Trial: Did Emory Get Caught in the Hype?
Novocure's LUNAR Trial presented at ASCO23 led to a dramatic drop in the stock price of NVCR. Following ASCO23, Emory University continued to praise the LUNAR s…
Prepare for Social Discussion of #ASCO24
KOL Pulse AI is a social listening tool for ASCO24. It provides Digital opinion leader and key opinion leader profiles and provides their social sentiment analy…
Digital KOLs of #ASH23
#ASH23 digital key opinion leaders (KOLS) led the way with a collaborative online learning community to support the powerful presentations of the hematology res…
Hematology KOLs Rally Behind CAR-T Cost Effectiveness Study
Hematology experts from around the world discuss the cost-effectiveness of CAR-T therapy based on new Dana-Farber Cancer Center Study
KOL Pulse AI- The Ultimate Tool for Identifying and Analyzing Key Opinion Leaders in Healthcare
Discover how the innovative KOL Pulse app helps marketers identify healthcare key opinion leaders, and curate Twitter conversations from Medical Meetings
The Sci Fi Nightmare of AI and Patient Claims Data
Could an uncontrolled artificial intelligence application using patient claims data hack the US Healthcare System?
The Digital KOL - How Are They Different?
Biotech, Medical Device and Pharma companies must adapt to the growing influence of Digital Opinion Leaders. Social Monitoring is a key task of MSLs.
The Digital KOLs of Interventional Neurology
SNIS2023 was an impressive meeting with leaders across the neurointervention community. Which Key Opinion Leaders generate the most engagement among radiologist…